S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
NASDAQ:AZYO

Aziyo Biologics Stock Forecast, Price & News

$5.40
-1.00 (-15.63%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.39
$6.30
50-Day Range
$4.10
$7.14
52-Week Range
$4.10
$18.20
Volume
63,505 shs
Average Volume
9,193 shs
Market Capitalization
$55.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.8
30 days | 90 days | 365 days | Advanced Chart
Receive AZYO News and Ratings via Email

Sign-up to receive the latest news and ratings for Aziyo Biologics and its competitors with MarketBeat's FREE daily newsletter.


Aziyo Biologics logo

About Aziyo Biologics

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Headlines

Aziyo Biologics Announces $14.0 Million Private Placement
December 6, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZYO
Employees
163
Year Founded
N/A

Sales & Book Value

Annual Sales
$42.68 million
Book Value
$2.04 per share

Profitability

Net Income
$-21.83 million
Pretax Margin
-43.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
5,641,000
Market Cap
$55.39 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
1/24/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.58 out of 5 stars

Medical Sector

98th out of 1,415 stocks

Biological Products, Except Diagnostic Industry

13th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -












Aziyo Biologics (NASDAQ:AZYO) Frequently Asked Questions

Is Aziyo Biologics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aziyo Biologics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aziyo Biologics stock.
View analyst ratings for Aziyo Biologics
or view top-rated stocks.

Are investors shorting Aziyo Biologics?

Aziyo Biologics saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 1,800 shares, a decline of 88.4% from the December 15th total of 15,500 shares. Based on an average daily volume of 16,700 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company's stock are short sold.
View Aziyo Biologics' Short Interest
.

When is Aziyo Biologics' next earnings date?

Aziyo Biologics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Aziyo Biologics
.

How were Aziyo Biologics' earnings last quarter?

Aziyo Biologics, Inc. (NASDAQ:AZYO) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.19. The company earned $11.49 million during the quarter, compared to analyst estimates of $11.54 million. Aziyo Biologics had a negative trailing twelve-month return on equity of 140.59% and a negative net margin of 43.12%. During the same period in the prior year, the business earned ($15.79) earnings per share.
View Aziyo Biologics' earnings history
.

What guidance has Aziyo Biologics issued on next quarter's earnings?

Aziyo Biologics issued an update on its FY 2021 earnings guidance on Tuesday, December, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $47 million-$48 million, compared to the consensus revenue estimate of $48.72 million.

What price target have analysts set for AZYO?

2 brokers have issued 1-year price objectives for Aziyo Biologics' stock. Their forecasts range from $11.00 to $11.00. On average, they expect Aziyo Biologics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price.
View analysts' price targets for Aziyo Biologics
or view top-rated stocks among Wall Street analysts.

Who are Aziyo Biologics' key executives?

Aziyo Biologics' management team includes the following people:
  • Mr. Ronald K. Lloyd, CEO, Pres & Director (Age 60, Pay $890.57k) (LinkedIn Profile)
  • Dr. Darryl Roberts Ph.D., Exec. VP of Operations & Product Devel. (Age 60, Pay $468.24k)
  • Dr. Jerome Riebman FACC, M.A., M.D., Chief Medical Officer (Age 67, Pay $552.69k)
  • Mr. Matthew B. Ferguson, Chief Financial Officer (Age 53) (LinkedIn Profile)
  • Ms. Courtney Guyer, VP of Marketing
  • Mr. Thomas Englese, Chief Commercial Officer (Age 47)
  • Mr. Jeffry D. Hamet, VP of Fin., Treasurer & Sec.

When did Aziyo Biologics IPO?

(AZYO) raised $49 million in an initial public offering on Thursday, October 8th 2020. The company issued 2,900,000 shares at a price of $16.00-$18.00 per share. Piper Sandler and Cowen acted as the underwriters for the IPO and Cantor and Truist Securities ​ were co-managers.

What is Aziyo Biologics' stock symbol?

Aziyo Biologics trades on the NASDAQ under the ticker symbol "AZYO."

How do I buy shares of Aziyo Biologics?

Shares of AZYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aziyo Biologics' stock price today?

One share of AZYO stock can currently be purchased for approximately $5.40.

How much money does Aziyo Biologics make?

Aziyo Biologics has a market capitalization of $55.39 million and generates $42.68 million in revenue each year. The company earns $-21.83 million in net income (profit) each year or ($2.11) on an earnings per share basis.

How many employees does Aziyo Biologics have?

Aziyo Biologics employs 163 workers across the globe.

What is Aziyo Biologics' official website?

The official website for Aziyo Biologics is www.aziyobiologics.com.

How can I contact Aziyo Biologics?

The company can be reached via phone at 240-247-1143, via email at [email protected], or via fax at 510-307-9896.


This page was last updated on 1/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.